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INTRODUCTION
Hedgehogs appear particularly prone to neoplasia. Usually 
these tumours occur in animals that are over 3 years in age, 
with malignancy incidence between 65-85%. Despite the 
number of tumour descriptions in hedgehogs, there is no lit-
erature concerning chemotherapy in this specie, and treat-
ments are generally extrapolated from cats and dogs 
protocols.
CLINICAL CASE
A 2,5 year-old intact female African hedgehog (Atelerix Albi-
ventris), was evaluated for abdominal distension. On physical 
examination the animal weighed 546g and a firmly mass was 
palpated along the abdomen measuring 7cm in diameter.
Haematology, biochemistry, radiographs, ultrasonogra-
phy (US) and a computed tomography (CT) were performed. 
Complete blood cell revealed a neutrophilic leukocytosis but 
the chemistry profile results were within the normal ranges. 
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Idiopathic chylothorax is a rare disease that affects cats. Dif-
ferent therapeutical options both surgical and medical have 
been described without a clear standard protocol and posi-
tive outcome.
were apparent months earlier (two months- one year) and 
veterinary care was not sought possibly due to their insidi-
ous onset. Development of diabetes mellitus in hypothyroid 
dogs is either due to insulin resistance or immune-mediated 
destruction of pancreatic b-cells. Polyglandular autoimmune 
syndrome was strongly suspected in 2/3 of these patients.
Radiographic images revealed a large soft tissue opacity 
occupying the entire abdominal cavity. US identified a mass 
with small cystic areas (larger than 4x3cm) in the middle-
caudal abdomen. CT confirmed a large abdominal mass 
(about 7x5cm) affecting the uterus, causing mass effect and 
dorsolateral displacement of the intestinal package, spleen 
and right kidney. The mass had well-defined margins, and 
was causing marked thickening and nodular appearance of 
the left uterine horn wall.
An exploratory laparotomy was performed and a large 
mass englobing uterus and ovaries was removed. Histo-
pathological examination identified a uterine leiomyo-
sarcoma.
Fourteen days postoperatively the animal started metro-
nomic chemotherapy with toceranib phosphate (Palladia®) 
2.5mg/animal every other day, but due to haematological 
changes over weeks, it was administered every 4 days.
Six months later the animal was active, eating and drink-
ing as normally. At that time a US and a CT revealed several 
masses spread into the omentum. The cytology and biopsy 
of some masses confirmed the diagnosis of sarcoma. The 
animal went on toceranib phosphate, 2.5mg/animal every 4 
days and cyclophosphamide, administered subcutaneously, 
was added every 3 weeks.
Several weeks later, the animal is well.
CONCLUSIONS
The elective treatment for uterine neoplasia is an ovariohys-
terectomy but depending of the malignity of the tumour an 
adjunctive chemotherapy should be performed. Toceranib 
phosphate and cyclophosphamide were administered to the 
hedgehog because a good response has been observed in 
dogs with similar solid tumours. In the present case, although 
a decrease in hematocrit was observed, a clinical benefit was 
evident. To the authors knowledge this is the first report of a 
metronomic chemotherapy in an African hedgehog.
The use of Octreotide in cats have been described previ-
ously (for the medical therapy of hyperinsulinemia in cats 
affected by insulinomas, gastrinomas, acromegaly and acute 
pancreatitis) but its usefulness as definitive treatment to cure 
chylothorax its unclear. This preliminary data describe the 
clinical features of three cats treated with Octreotide after a 
partial surgical resolution of idiopathic chylothorax.
Three cats presenting a moderate amount of chylous 
effusion one week after surgical closure of thoracic duct with 
transdiaphragmatic approach were selected for our study. 
The Octreotide started seven days after surgery at the dose 
of 20 ug/kg/sc/tid (dose proposed in literature 10–20 ug/kg/
sc/tid for maximum 2–3 weeks). Standard clinical, radio-
graphic and ultrasonographic evaluations were performed 
twice a month and together blood cell count, seroum bio-
chemistry, cytological,chemical-physical evaluation of tho-
racic effusion were performed at each control. Clinical, 
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BACKGROUND
Although experimental canine models are commonly used 
to investigate bone pathology associated with specific lyso-
somal storage disorders, only a few reports have described 
such changes in naturally affected dogs. These disorders 
are most typically caused by homogenous recessive genetic 
abnormalities, resulting in enzyme deficiencies an subse-
quent accumulation of storage material within the cell. Ani-
mals will be born normal and clinical signs will become 
apparent as they age. Although many body systems are 
involved, affected animals typically present with clinical 
signs of central nervous system dysfunction.
CASE PRESENTATION
A 3-year-11-month male neutered Rhodesian ridgeback was 
presented for evaluation of cervical hyperaesthesia and right 
thoracic limb lameness. Neurological examination identified 
imaging and laboratory abnormalities were reported.
The Octreotide administration was interrupted one 
month later by the end of the pleural collection and each 
patients was re-evaluated one year after surgery.
Cat one: (DSH, 5 years old, neutered male) presented 
pleural effusion from day one to day 146 of therapy. Octreo-
tide was interrupted at day 176.
Cat two: (DSH, 6 years old, neutered male) presented 
pleural effusion from day one to day 143 of therapy. Octreotide 
was interrupted at day 173. Both cats were discharged with-
out clinical symptoms and they were rechecked six month 
later without any clinical problems, except the diffuse pleural 
thickening observed at the ultrasonographic examination.
Cat three: (DSH, 9 years old, neutered male) presented 
pleural effusion from day one to day 182 of octreotide ther-
apy. At day 182 the cat was euthanised according to the 
owners due to respiratory insufficiency. Necropsy confirmed 
a severe constrictive pleuririts. In all the subject thoracente-
sis were performed during controls if necessary.
No adverse effects were observed even considering 
that this drug was used for 6 months therapy. In our experi-
ence on three cats the use of Octreotide turned out useful 
and safe as complementary therapy of the idiopathic chylo-
thorax.
generalised ataxia, right thoracic limb lameness, proprio-
ceptive deficits in both pelvic limbs and marked cervical 
hyperaesthesia. A lesion affecting the C1-C5 spinal cord 
segments was considered likely. MRI of the neck identified 
an irregularly shaped and shortened vertebral body of C6, a 
mild subluxation between C5 and C6, multiple hypertrophic 
and abnormally shaped articular processes, and multiple 
dorsal lamina abnormalities. CT identified generalised verte-
bral abnormalities, which were most pronounced in the cer-
vical vertebral column. Multiple cervical vertebrae were 
abnormally shaped, consisting of hypertrophic and abnor-
mally shaped articular processes, dorsal lamina, irregularly 
shaped vertebral bodies, and multiple visible fractures lines. 
The axial and appendicular skeleton were characterised by 
abnormally hypoattenuating cancellous bone and a thin cor-
tical cortex. The dog was euthanised and a post-mortem 
examination confirmed generalized osteoporosis, vertebral 
malformations and identified distended and swollen neurons 
in the cerebrum, hippocampus, cerebellum and brainstem, 
containing intracytoplasmic, granular, PAS-positive inclu-
sions. These findings were considered consistent with a lys-
osomal storage disease, with a presumptive diagnosis of 
mucopolysacharidosis being most likely.
CONCLUSION
This report describes vertebral MRI and CT abnormalities in 
a dog with a lysosomal storage disease and illustrates that 
this type of disorders should be considered in dogs of any 
breed and age with generalized vertebral abnormalities and 
osteoporosis.
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Biomarkers have the potential to facilitate assessment of spi-
nal cord injuries, assist clinical decision-making, and further 
improve understanding of the pathophysiology of spinal cord 
injury (SCI). Urine is an attractive source of potential biomark-
ers due to its relative ease of collection and potentially high 
protein content. A pilot study suggested that transthyretin 
(TTR) is present in urine of dogs with SCI, while clusterin in 
cerebrospinal fluid has been proposed as a biomarker of 
chronic spinal cord disease in the dog and it is also detecta-
ble in urine. This project investigated the potential of urinary 
TTR and clusterin as biomarkers of SCI. Random spot urine 
samples were collected from clinically healthy dogs, as well as 
dogs with spinal cord injury (n = 12) and a variety of non- 
neurological conditions (7 healthy dogs, 2 dogs with 
